Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Gabapentin Enacarbil PK in Healthy Males
NCT02632331Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2009
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gabapentin enacarbil in restless legs syndrome (RLS) and postherpetic neuralgia (PHN) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Curve to the Last Measurable Concentration at 48 hours and 4 more. Started Jan 2009; status: completed.
02
Drugs
gabapentin enacarbil
03
Conditions
restless legs syndrome (RLS)postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT02632331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632331.